GlassScriptPhysician profile
Natasha Salazar
NPI 1215401674
$31,111.53
in general payments reported to CMS, 2019-2025
85 companies · $7,460 in 2025
The $7,460 reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,928 · 2022: $5,648 · 2023: $6,578 · 2024: $7,497 · 2025: $7,460.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $19K · Long Term Medical Supply Or Device Loan: $2,266 · Education: $652.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $18,617.11 |
| Long Term Medical Supply Or Device Loan | $2,266.28 |
| Education | $652.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $4,366.19 | 2021-2025 | |
| Eisai INC. | $1,732.30 | 2021-2025 | |
| Incyte Corporation | $1,675.21 | 2021-2025 | Jakafi, Monjuvi, Pemazyre |
| Janssen Biotech, INC. | $1,403.91 | 2021-2025 | Darzalex, Tecvayli, Imbruvica |
| Astrazeneca Pharmaceuticals LP | $1,223.37 | 2021-2025 | Imfinzi, Calquence, Enhertu |
| Pfizer INC. | $1,194.16 | 2021-2025 | |
| Celgene Corporation | $1,129.20 | 2021-2025 | Reblozyl, Pomalyst, Opdualag |
| E.R. Squibb & Sons, L.L.C. | $1,090.84 | 2021-2025 | Opdivo, Opdualag, Reblozyl |
| Merck Sharp & Dohme LLC | $1,054.31 | 2021-2025 | Keytruda, Welireg, Lynparza |
| Takeda Pharmaceuticals U.S.A., INC. | $889.84 | 2021-2025 | Fruzaqla, Alunbrig, Iclusig |
| Lilly USA, LLC | $775.26 | 2021-2025 | Jaypirca, Verzenio, Retevmo |
| Astellas Pharma US INC | $741.84 | 2021-2025 | Xtandi, Xospata, Vyloy |
| Bayer Healthcare Pharmaceuticals INC. | $718.33 | 2021-2025 | |
| Daiichi Sankyo INC. | $716.66 | 2021-2025 | Enhertu, Datroway, Injectafer |
| Glaxosmithkline, LLC. | $681.48 | 2021-2025 | Ojjaara, Jemperli, Zejula |
Show all 85 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $663.75 | 2021-2025 | |
| Seagen INC. | $612.26 | 2021-2025 | Tukysa, Padcev, Tivdak |
| Sobi, INC | $611.41 | 2022-2025 | |
| Amgen INC. | $593.82 | 2021-2025 | Kyprolis, Blincyto, Lumakras |
| Genzyme Corporation | $512.87 | 2021-2025 | |
| Gilead Sciences, INC. | $496.29 | 2022-2025 | Trodelvy |
| Karyopharm Therapeutics INC. | $486.95 | 2021-2025 | Xpovio |
| Pharmacyclics LLC, An Abbvie Company | $470.76 | 2021-2023 | Imbruvica, Epkinly |
| Exelixis INC. | $406.39 | 2021-2025 | Cabometyx |
| Regeneron Healthcare Solutions, INC. | $401.81 | 2021-2025 | Libtayo |
| Genentech USA, INC. | $361.35 | 2021-2025 | Phesgo, Tecentriq, Polivy |
| Array Biopharma INC | $326.40 | 2021-2025 | Mektovi, Braftovi, Tukysa |
| Puma Biotechnology, INC. | $294.96 | 2021-2025 | |
| Sumitomo Pharma America, INC. | $294.77 | 2023-2025 | Orgovyx |
| Pharmaessentia USA Corporation | $286.96 | 2022-2025 | Besremi |
| Aveo Pharmaceuticals, INC. | $267.85 | 2021-2025 | Fotivda |
| Stemline Therapeutics INC. | $265.36 | 2021-2025 | Orserdu |
| Beigene USA, INC. | $258.45 | 2021-2025 | Brukinsa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $244.50 | 2021-2025 | Gilotrif |
| Rigel Pharmaceuticals, INC. | $230.73 | 2021-2025 | Rezlidhia, Tavalisse, Gavreto |
| Kite Pharma, INC. | $202.28 | 2021-2025 | Yescarta |
| Emd Serono, INC. | $197.86 | 2021-2025 | Bavencio |
| Cti Biopharma Corp. | $183.99 | 2022-2023 | Vonjo |
| Servier Pharmaceuticals LLC | $183.26 | 2021-2025 | |
| Alexion Pharmaceuticals, INC. | $180.77 | 2021-2025 | Ultomiris |
| Syndax Pharmaceuticals, INC. | $176.79 | 2025 | Revuforj |
| Taiho Oncology, INC. | $152.90 | 2022-2025 | |
| Recordati_rare_diseases_inc. | $148.39 | 2023-2025 | Enjaymo, Sylvant |
| Blueprint Medicines Corporation | $143.19 | 2021-2025 | Ayvakit |
| Myovant Sciences INC. | $140.25 | 2021-2022 | |
| Ipsen Biopharmaceuticals, INC | $132.11 | 2021-2024 | Onivyde, Somatuline Depot, Tazverik |
| Morphosys, US INC. | $129.73 | 2022-2024 | Monjuvi |
| Sanofi-Aventis U.S. LLC | $99.99 | 2023 | |
| Agios Pharmaceuticals, INC. | $87.63 | 2023-2025 | Pyrukynd |
| Dendreon Pharmaceuticals LLC | $84.79 | 2021-2024 | Provenge |
| Ge Healthcare | $82.38 | 2021-2022 | |
| Azurity Pharmaceuticals, INC. | $80.77 | 2025 | Danziten |
| Csl Behring | $73.26 | 2021 | |
| Kyowa Kirin, INC. | $73.22 | 2023-2025 | Poteligeo |
| Geron Corporation | $71.92 | 2025 | Rytelo |
| Adaptive Biotechnologies Corporation | $67.96 | 2023 | Clonoseq |
| Iovance Biotherapeutics, INC. | $67.08 | 2024-2025 | Amtagvi |
| Dova Pharmaceuticals | $62.89 | 2021 | |
| Alnylam Pharmaceuticals INC. | $51.68 | 2022-2023 | Givlaari |
| G1 Therapeutics, INC. | $49.58 | 2022 | |
| Pharmacosmos Therapeutics INC. | $47.79 | 2025 | Monoferric |
| Janssen Scientific Affairs, LLC | $47.65 | 2023 | Darzalex, Imbruvica |
| Global Blood Therapeutics, INC. | $46.81 | 2021 | |
| Eusa Pharma (US) LLC | $38.87 | 2021 | |
| Immunogen, INC. | $38.57 | 2023-2024 | Elahere, Elahere |
| Emmaus Medical, INC. | $34.09 | 2023 | Endari |
| Cumberland Pharmaceuticals, INC. | $32.99 | 2023-2025 | Sancuso |
| Octapharma USA, INC. | $32.97 | 2022 | |
| Mirati Therapeutics, INC. | $32.72 | 2023 | Krazati |
| Coherus Oncology, INC. | $27.61 | 2025 | Loqtorzi |
| Progenics Pharmaceuticals, INC. | $27.58 | 2023 | Pylarify |
| Tersera Therapeutics LLC | $25.21 | 2025 | Zoladex |
| Pharmaand Gmbh | $25.18 | 2025 | Rubraca |
| Deciphera Pharmaceuticals INC. | $23.79 | 2025 | Qinlock, Romvimza |
| Amneal Pharmaceuticals LLC | $23.55 | 2023 | Neupogen, Avastin, Neulasta |
| Novocure INC. | $23.50 | 2021 | |
| Amag Pharmaceuticals, INC. | $22.76 | 2021 | |
| Macrogenics, INC. | $22.52 | 2021 | |
| Tolmar, INC. | $21.95 | 2025 | Eligard |
| Adc Therapeutics America, INC. | $19.75 | 2024 | |
| Organon LLC | $19.69 | 2022 | |
| Janssen Pharmaceuticals, INC | $19.17 | 2022-2023 | Xarelto |
| Epizyme, INC. | $19.04 | 2022 | |
| Chiesi USA, INC. | $16.80 | 2023 | Ferriprox |
| Acrotech Biopharma INC. | $15.76 | 2021 |
Drugs and devices associated with these payments
Kisqali $2,471Lenvima $1,259Imbruvica $870Keytruda $824Enhertu $678Jakafi $572Darzalex $564Jaypirca $531Verzenio $508Vonjo $495Tecvayli $415Reblozyl $395Xtandi $385Opdivo $381Stivarga $369Orgovyx $365Imfinzi $350Vitrakvi $329Fruzaqla $312Epkinly $302Ojjaara $298Monjuvi $287Tukysa $281Lynparza $273Padcev $272Scemblix $264Libtayo $247Cabometyx $246Alunbrig $244Welireg $242Xpovio $240Calquence $228Pomalyst $225Trodelvy $222Pluvicto $215Orserdu $206Opdualag $206Retevmo $204Sarclisa $202Brukinsa $196Braftovi $191Mektovi $191Nubeqa $186Jemperli $184Ibrance $184Talvey $184Pemazyre $178Inlyta $176Doptelet $174Carvykti $174Talzenna $169Besremi $162Xospata $158Fabhalta $149Tavalisse $148Rezlidhia $148Fotivda $147Revuforj $143Ultomiris $139Lutathera $133Phesgo $122Zejula $119Elitek $118Iclusig $111Tecentriq $108Adcetris $104Piqray $103Polivy $103Gilotrif $102Lonsurf $93.65Inqovi $93.65Onivyde $93.07Somatuline Depot $93.07Ayvakit $89.81Enjaymo $89.25Erleada $87.99Pyrukynd $87.63Lorbrena $84.40Nerlynx $83.36Danziten $80.77Yescarta $80.48Promacta $77.27Poteligeo $73.22Vyloy $72.02Rytelo $71.92Venclexta $71.70Clonoseq $67.96Elahere $67.80Amtagvi $67.08Ninlaro $64.31Zynyz $62.13Elrexfio $60.05Sylvant $59.14Wayrilz $57.69Tivdak $55.39Datroway $55.32Mekinist $55.08Alecensa $54.03Monoferric $47.79Xalkori $45.87
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Natasha Salazar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.